Boundless Bio Inc stock is traded at $2.40, with a volume of 9,486. It is down -0.41% in the last 24 hours and down -6.61% over the past month. Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
Previous Close:
$2.41
Open:
$2.41
24h Volume:
9,486
Relative Volume:
0.11
Market Cap:
$55.65M
Revenue:
-
Net Income/Loss:
-$55.99M
P/E Ratio:
-
EPS:
-$2.50
Net Cash Flow:
-$47.60M
1W Performance:
-2.83%
1M Performance:
-6.61%
6M Performance:
+51.90%
1Y Performance:
+90.48%
1-Day Range:
$2.38$2.41
1-Week Range:
$2.38$2.55
52-Week Range:
$0.9612$3.16
Boundless Bio Inc Stock (BOLD) Company Profile
Name
Boundless Bio IncSector
HealthcareIndustry
BiotechnologyPhone
(858) 766-9912Address
10955 ALEXANDRIA WAY, SAN DIEGO, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS